Oxyglobin Evropska unija - slovenščina - EMA (European Medicines Agency)

oxyglobin

opk biotech netherlands bv - hemoglobin glutamer-200 (govedo) - nadomestki krvi in perfuzijske raztopine - psi - oxyglobin zagotavlja psom, ki nosi kisik, ki izboljša klinične znake anemije vsaj 24 ur, ne glede na osnovno stanje.

Ultomiris Evropska unija - slovenščina - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinurija, paroksizmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Trifexis Evropska unija - slovenščina - EMA (European Medicines Agency)

trifexis

eli lilly and company limited - spinosad, milbemycin oxime - antiparasitic izdelkov, insekticidi in repelenti, endectocides - psi - za zdravljenje in preprečevanje bolh (ctenocephalides felis) infestations pri psih, kjer eden ali več od naslednjih navedb so potrebne hkrati: preprečevanje heartworm bolezni (l3, l4 dirofilaria immitis);preprečevanje angiostrongylosis za zmanjšanje stopnje okužbe z nezreli odraslih (l5) angiostrongylus vasorum;zdravljenje prebavnih nematode okužb, ki jih povzročajo hookworm (l4, nezreli odraslih, l5) in odrasli ancylostoma caninum), roundworms (nezrel odraslih l5 in odraslih toxocara canis in odraslih toxascaris leonina) in whipworm (za odrasle trichuris vulpis).

Soliris Evropska unija - slovenščina - EMA (European Medicines Agency)

soliris

alexion europe sas - eculizumab - hemoglobinurija, paroksizmal - imunosupresivi - soliris je navedeno pri odraslih in otrocih za zdravljenje:paroxysmal nočne haemoglobinuria (pnh). dokazila o kliničnih koristi je dokazana pri bolnikih z haemolysis z klinični simptom(i) okvirni visoke aktivnosti bolezni, ne glede na to, transfuzijo zgodovine (glej poglavje 5. netipične haemolytic uremic sindrom (ahus). soliris je navedeno pri odraslih za zdravljenje:ognjevzdržni splošnih myasthenia gravis (gmg) pri bolnikih, ki so anti-receptorjev acetilholina (achr) protitelesa-pozitivna (glej poglavje 5. neuromyelitis optica spectrum disorder (nmosd) pri bolnikih, ki so anti-aquaporin-4 (aqp4) protitelesa-pozitivno z recidivno potek bolezni.

Epysqli Evropska unija - slovenščina - EMA (European Medicines Agency)

epysqli

samsung bioepis nl b.v. - eculizumab - hemoglobinurija, paroksizmal - imunosupresivi - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

EPREX 5000 i.e./0,5 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eprex 5000 i.e./0,5 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah

johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 5000 i.e. / 0,5 ml - eritropoetin

EPREX 6000 i.e./0,6 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eprex 6000 i.e./0,6 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah

johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 6000 i.e. / 0,6 ml - eritropoetin

EPREX 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eprex 30.000 i.e./0,75 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah

johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje v napolnjeni injekcijski brizgi - epoetin alfa 30000 i.e. / 0,75 ml - eritropoetin

EPREX 40.000 i.e./1,0 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eprex 40.000 i.e./1,0 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah

johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 40000 i.e. / 1 ml - eritropoetin

EPREX 8000 i.e./0,8 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

eprex 8000 i.e./0,8 ml raztopina za injiciranje v napolnjenih injekcijskih brizgah

johnson & johnson d.o.o. - epoetin alfa - raztopina za injiciranje - epoetin alfa 8000 i.e. / 0,8 ml - eritropoetin